{"certainAgreement":{"otherDetails":"The principal investigator (PI) agrees not to publish/publicly present any interim study results without the sponsor's prior written consent. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication/presentation to permit the sponsor to review copies of abstracts or manuscripts for publication which report any results of the Study. The sponsor shall have the right to review and comment on any presentation, which shall include editorial rights.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"email":"ClinicalTrialsDisclosure@merck.com","organization":"Merck Sharp & Dohme Corp.","title":"Senior Vice President, Global Clinical Development"}}